111P Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours

Entrectinib is a CNS-active tyrosine kinase inhibitor (TKI) of ROS1 and TRK. Latest results from an integrated analysis of 3 phase 1/2 trials (ALKA-372-001 EudraCT 2012-000148-88; STARTRK-1 NCT02097810; STARTRK-2 NCT02568267) show that entrectinib has efficacy in pts with ROS1-fp NSCLC (objective response rate [ORR] 67.1%; 1 May 2019 cutoff) and NTRK-fp solid tumours (ORR 61.2%; 31 Aug 2020 cutoff). We report primary results for the subset of Chinese (mainland China, HK, Taiwan) pts from STARTRK-2 (17 Jun 2021 cutoff).